Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Validation of a prognostic multi‐gene signature in high‐risk neuroblastoma using the high throughput digital NanoString nCounter™ system

31 Jan 2014

Abstract excerpt

Microarray-based molecular signatures have not been widely integrated into neuroblastoma diagnostic classification systems due to the complexities of the assay and requirement for high-quality RNA. New digital technologies that accurately quantify gene expression using RNA isolated from formalin-fixed paraffin embedded (FFPE) tissues are now available. In this study, we describe the first use of a high-throughput...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Neuroblastoma Research and Treatments
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24560446
DOI: 10.1016/j.molonc.2014.01.010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Validation of a prognostic multi‐gene signature in high‐risk neuroblastoma using the high throughput digital NanoString nCounter™ systemPMID 24560446Read ↗

Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene SignatureSemantic proximity Read ↗

Prediction of Clinical Outcome Using Gene Expression Profiling and Artificial Neural Networks for Patients with NeuroblastomaSemantic proximity Read ↗

Customized Oligonucleotide Microarray Gene Expression–Based Classification of Neuroblastoma Patients Outperforms Current Clinical Risk StratificationSemantic proximity Read ↗

High-risk, Expression-Based Prognostic Long Noncoding RNA Signature in NeuroblastomaSemantic proximity Read ↗

miRNA Expression Profiling Enables Risk Stratification in Archived and Fresh Neuroblastoma Tumor SamplesSemantic proximity Read ↗

Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomasSemantic proximity Read ↗

A Three-Gene Expression Signature Model for Risk Stratification of Patients with NeuroblastomaSemantic proximity Read ↗

Comparison of RNA-seq and microarray-based models for clinical endpoint predictionSemantic proximity Read ↗

International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology CommitteeSemantic proximity Read ↗

Transcriptomic profiling of 39 commonly-used neuroblastoma cell lines.Semantic proximity Read ↗

A comparative network analysis of high-risk MYCN amplified and high-risk MYCN non-amplified neuroblastoma patientsSemantic proximity Read ↗

Prognostic Impact of Gene Expression–Based Classification for NeuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.